Ultragenyx Pharmaceutical Inc’s filing revealed that its Director Sanders Corazon (Corsee) D. unloaded Company’s shares for reported $89923.0 on Jun 20 ’25. In the deal valued at $37.39 per share,2,405 shares were sold. As a result of this transaction, Sanders Corazon (Corsee) D. now holds 15,344 shares worth roughly $0.42 million.
Then, CORAZON D. SANDERS bought 2,405 shares, generating $89,923 in total proceeds.
Before that, Crombez Eric sold 520 shares. Ultragenyx Pharmaceutical Inc shares valued at $20,405 were divested by the EVP and Chief Medical Officer at a price of $39.24 per share. As a result of the transaction, Crombez Eric now holds 71,530 shares, worth roughly $1.96 million.
A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late May with a ‘”an Outperform”‘ rating. Goldman also remained covering RARE and has increased its forecast on June 06, 2024 with a “Buy” recommendation from previously “Neutral” rating. RBC Capital Mkts started covering the stock on April 22, 2024. It rated RARE as “an Outperform”.
Price Performance Review of RARE
On Monday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock fall -0.54% to $27.39. Over the last five days, the stock has lost -3.76%. Ultragenyx Pharmaceutical Inc shares have fallen nearly -44.03% since the year began. Nevertheless, the stocks have fallen -34.89% over the past one year. While a 52-week high of $60.37 was reached on 02/06/25, a 52-week low of $25.81 was recorded on 07/21/25.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 27.07, which if violated will result in even more drops to 26.74. On the upside, there is a resistance level at 27.65. A further resistance level may holdings at 27.91.
How much short interest is there in Ultragenyx Pharmaceutical Inc?
A steep rise in short interest was recorded in Ultragenyx Pharmaceutical Inc stocks on 2025-07-15, growing by 2.72 million shares to a total of 8.8 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 6.08 million shares. There was a rise of 30.91%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 08, 2023 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $72 price target.
